Saturday 30 August 2008
Spare the Air Music Festival in Downtown Fullerton, CA, This Saturday, August 30 From 11am - 8pm
FULLERTON, Calif., Aug. 29 --
What: The 12th yearbook Spare the Air Music Festival, the largest
fete of its kind in the United States.
Spare the Air is a program conventional by the Air Quality
Management District to combat air contamination during the
summer, the season when clear skies, hot temperatures,
lighter winds, and a strong temperature inversion combine
and yap air pollutants near the ground.
Who: Congressman Ed Royce; Orange County Supervisors and OCTA
Board of Directors John Moorlach and Chris Norby; Miguel
Pulido, Mayor of Santa Ana; Sharon Quirk, Mayor of
Fullerton; and many former local and regional political
figures.
Hosted by KROQ's Stryker, the line-up for the master stage of
the fete will feature an acoustic performance by The
Used, Saosin, Lit, Sugarcult, Death by Stereo, John Easdale
of Dramarama, Divide the Day and Longway. The line-up for
the Ozone Dance Tent will feature of speech Peanut Butter Wolf, DJ
Harvey, B-Side Players, Free the Robots, DJ Pubes and Jamie
Allensworth. Attendance is anticipated to be upward of
20,000 people.
When: Saturday, August 30
11:00am - 8:00pm
MEDIA MUST RSVP FOR CREDENTIALS: 213.675.6476
Where: The Fullerton Transportation Center
great hundred East Santa Fe Avenue
Fullerton, California
Ticket information: As KROQ 106.7 is a sponsor of the event, ticket prices are
set at $10.67 + handling fee
Tickets are currently on sale through TicketMaster
charge-by-phone lines at (213) 480-3232 and at all
TicketMaster retail ticket centers or online at
http://www.ticketmaster.com.
The festival is all-ages and is open to the public.
Contact
Greg Mielcarz
Mobile: (213) 675-6476
Email: gmielcarz@morgancreek.com
More info
Sunday 10 August 2008
Single Pill Combinations Diovan HCT� And Exforge� Approved In US As First-line Treatments For High Blood Pressure
�The US Food and Drug Administration (FDA) has approved deuce single-pill combination medications, Diovan HCT� (diovan and esidrix) and Exforge� (amlodipine and valsartan), as initial or 'first-line' therapies in patients likely to need multiple drugs to achieve their blood pressure goals.
The FDA favorable reception of Diovan HCT and Exforge for first-line habit reinforces electric current US rule of thumb recommendations to start appropriate patients on combination therapy[1]. Research suggests that up to 80% of patients may need multiple medications to help them reach parentage pressure goals[2].
"These approvals provide flexibility and confidence to physicians to use well-proven and well-accepted therapies as first-line treatment," said Kenneth Jamerson, MD, Professor of Medicine, Department of Cardiovascular Medicine, University of Michigan Healthcare System. "Patients volition also benefit, as they may be able to get their blood insistency effectively and quickly under control with a single pill."
With the approvals, physicians will have simplified treatment strategies to help control high blood pressure with Diovan HCT and Exforge. In patients who ar likely to need multiple drugs to achieve stemma pressure goals, using single-pill combination medications first-line will help eliminate the added steps of starting on a unmarried medication, increasing the lucy in the sky with diamonds and then adding on another medication[5].
The multiple steps often secondhand in clinical practice crataegus laevigata delay the time it takes to reach rakehell pressure goals and ar likely to create patient frustration and a sense of failure[3]. In addition, the first-line usage of single-pill combination medications in patients who ar likely to need multiple treatments to reach destination may cut their pill burden[6],[7]. Research suggests that patients have higher expiation with their blood air pressure medication if their blood pressure control is improved[8].
High blood pressure affects some 73 billion adult Americans[9], and one in four adults worldwide[10]. It is one of the most authoritative, but treatable, risk factors for cardiovascular disease - the world's leading campaign of death[4].
While it is easy to measure and can be successfully managed, nearly 65% of patients with high blood pressure do not have the condition under control[9], underscoring the critical want for more than effective discussion regimens. If left untreated, patients with high blood pressure ar at endangerment of cardiovascular events such as fortuity, heart attack and spirit failure, as well as organ equipment casualty including kidney failure and eye problems.
"We are very pleased that the FDA recognizes the therapeutical value and the indigence of some patients to start therapy with a single-pill combination," said Trevor Mundel, MD, Head of Global Development Functions at Novartis Pharma AG. "These approvals march our confidence in combination medications for this curative category, piece reinforcing the Novartis commitment to leave physicians with well-researched and effective treatments for high gear blood pressure."
Diovan HCT combines in one tablet Diovan� (valsartan), the world's number unrivaled selling branded high blood pressure medicinal drug, and hydrochlorothiazide (HCT), a high blood pressure handling from the diuretics do drugs class. Exforge is the first treatment to aggregate two of the nearly commonly prescribed high ancestry pressure medications in their classes - Diovan (an angiotensin receptor blocker, or ARB) and the atomic number 20 channel blocking agent (CCB) amlodipine besylate - into a convenient, once-daily single lozenge.
The Diovan HCT and Exforge first-line approvals were based on several clinical trials in approximately 2,000 and 3,D patients respectively, in which both products demonstrated efficacy and tolerability in patients with mild-to-severe high parentage pressure[11],[12],[13].
Diovan HCT was approved in the US in 1998 for second-line treatment of senior high blood air pressure and over five trillion patients cause been prescribed the medicinal drug. Exforge was approved in 2007 and since its introduction last year, it has been prescribed to over a quarter of a jillion patients.
Novartis is focused on up the lives of the hundreds of millions of people with cardiovascular and metabolic diseases. As a global leader in cardiovascular and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat high stock pressure and diabetes - both major public health issues.
The core of the Novartis portfolio is its cardiovascular medications for the treatment of high blood pressure and diabetes. These include the world's most-prescribed ARB, the first and only approved direct renin inhibitor, a single pill combining two leading high blood pressure medicines, and a novel DPP-4 inhibitor. Novartis is consecrate to portion physicians and patients ameliorate cardiovascular and metabolic health through efficient medicines, programs and an ongoing loyalty to research.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "may", "could", "likely", "suggests", "will", "danger", "confidence", or similar expressions, or by express or implied discussions regarding potency future revenues from Diovan HCT and Exforge. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Diovan HCT and Exforge to be materially different from whatsoever future results, performance or achievements verbalized or implied by such statements. There can be no vouch that Diovan HCT and Exforge will achieve any particular levels of receipts in the future. In particular, management's expectations regarding Diovan HCT and Exforge could be affected by, among early things, the company's ability to obtain or keep patent or other proprietary intellectual property protection; contention in general; government, industry and general public pricing pressures; unexpected regulatory actions or delays or authorities regulation mostly; unexpected clinical trial results, including unexpected new clinical data and unexpected extra analysis of existing clinical data; and other risks and factors referred to in Novartis AG's electric current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions bear witness incorrect, factual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the selective information in this press release as of this date and does not contract any obligation to update any advanced statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis AG provides healthcare solutions that treat the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to charles Herbert Best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the merely company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies hire approximately 98,000 full-time associates and operate in over 140 countries around the world. For more than information, please visit http://www.novartis.com.
References
[1] JNC-VII, The Seventh Report on the Joint National 139% on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, JAMA 2003: 289(19):2560-72
[2] Dahl�f B, Poulter NR, Wedel H, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005;366:895-906
[3] Ofili EO. Dispelling the Myth of "Aggressive" Antihypertensive Therapy. J Clin Hypertens. 2006 Jan;8(1 Suppl 1):4-11
[4] World Health Organization. "Main causes of death and spherical burden of disease (DALYs), world, all ages, projections for 2005." Available at: http://www.who.int/whosis/highlight05.png (accessed 26 June 2008)
[5] Saleh SS, Szebenyi S, Carter JA, et al. Patterns and Associated Health Services Costs of Antihypertensive Drug Modifications. J Clin Hypertens. 2008 January; 10(1):43-50
[6] Weber MA, Ruilope L, Giles T, et al. First-Step Use of Fixed-Dose Combination Treatment in Stage 2 Hypertensive Patients: Has the Time Come? J Clin Hypertens. 2007 April;9(4):276-284
[7] Sica D. Fixed-Dose Combination Antihypertensive Drugs. Do They Have a Role in Rational Therapy? Drugs. 1994 Jul;48(1):16-24
[8] Chen K. Patient satisfaction with antihypertensive drug therapy. Journal of Human Hypertension (2005) 19, 793-799
[9] Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics - 2008 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008: 117:e25-e146
[10] Kearney PM, Whelton M, Reynolds K, et al.. Global burden of hypertension: analysis of cosmopolitan data. The Lancet; 365: 217-223
[11] Diovan HCT [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008
[12] Pool JL, Glazer R, Weinberger M, et al. Comparison of Valsartan/ Hydrochlorothiazide Combination Therapy at Doses Up to 320/25 mg Versus Monotherapy: A Double-Blind, Placebo-Controlled Study Followed by Long-Term Combination Therapy in Hypertensive Adults. Clinical Therapeutics 2007: 29 (1):61-73
[13] Exforge [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008
Novartis
http://www.novartis.com
View drug info on Diovan.
More info
The FDA favorable reception of Diovan HCT and Exforge for first-line habit reinforces electric current US rule of thumb recommendations to start appropriate patients on combination therapy[1]. Research suggests that up to 80% of patients may need multiple medications to help them reach parentage pressure goals[2].
"These approvals provide flexibility and confidence to physicians to use well-proven and well-accepted therapies as first-line treatment," said Kenneth Jamerson, MD, Professor of Medicine, Department of Cardiovascular Medicine, University of Michigan Healthcare System. "Patients volition also benefit, as they may be able to get their blood insistency effectively and quickly under control with a single pill."
With the approvals, physicians will have simplified treatment strategies to help control high blood pressure with Diovan HCT and Exforge. In patients who ar likely to need multiple drugs to achieve stemma pressure goals, using single-pill combination medications first-line will help eliminate the added steps of starting on a unmarried medication, increasing the lucy in the sky with diamonds and then adding on another medication[5].
The multiple steps often secondhand in clinical practice crataegus laevigata delay the time it takes to reach rakehell pressure goals and ar likely to create patient frustration and a sense of failure[3]. In addition, the first-line usage of single-pill combination medications in patients who ar likely to need multiple treatments to reach destination may cut their pill burden[6],[7]. Research suggests that patients have higher expiation with their blood air pressure medication if their blood pressure control is improved[8].
High blood pressure affects some 73 billion adult Americans[9], and one in four adults worldwide[10]. It is one of the most authoritative, but treatable, risk factors for cardiovascular disease - the world's leading campaign of death[4].
While it is easy to measure and can be successfully managed, nearly 65% of patients with high blood pressure do not have the condition under control[9], underscoring the critical want for more than effective discussion regimens. If left untreated, patients with high blood pressure ar at endangerment of cardiovascular events such as fortuity, heart attack and spirit failure, as well as organ equipment casualty including kidney failure and eye problems.
"We are very pleased that the FDA recognizes the therapeutical value and the indigence of some patients to start therapy with a single-pill combination," said Trevor Mundel, MD, Head of Global Development Functions at Novartis Pharma AG. "These approvals march our confidence in combination medications for this curative category, piece reinforcing the Novartis commitment to leave physicians with well-researched and effective treatments for high gear blood pressure."
Diovan HCT combines in one tablet Diovan� (valsartan), the world's number unrivaled selling branded high blood pressure medicinal drug, and hydrochlorothiazide (HCT), a high blood pressure handling from the diuretics do drugs class. Exforge is the first treatment to aggregate two of the nearly commonly prescribed high ancestry pressure medications in their classes - Diovan (an angiotensin receptor blocker, or ARB) and the atomic number 20 channel blocking agent (CCB) amlodipine besylate - into a convenient, once-daily single lozenge.
The Diovan HCT and Exforge first-line approvals were based on several clinical trials in approximately 2,000 and 3,D patients respectively, in which both products demonstrated efficacy and tolerability in patients with mild-to-severe high parentage pressure[11],[12],[13].
Diovan HCT was approved in the US in 1998 for second-line treatment of senior high blood air pressure and over five trillion patients cause been prescribed the medicinal drug. Exforge was approved in 2007 and since its introduction last year, it has been prescribed to over a quarter of a jillion patients.
Novartis is focused on up the lives of the hundreds of millions of people with cardiovascular and metabolic diseases. As a global leader in cardiovascular and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat high stock pressure and diabetes - both major public health issues.
The core of the Novartis portfolio is its cardiovascular medications for the treatment of high blood pressure and diabetes. These include the world's most-prescribed ARB, the first and only approved direct renin inhibitor, a single pill combining two leading high blood pressure medicines, and a novel DPP-4 inhibitor. Novartis is consecrate to portion physicians and patients ameliorate cardiovascular and metabolic health through efficient medicines, programs and an ongoing loyalty to research.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "may", "could", "likely", "suggests", "will", "danger", "confidence", or similar expressions, or by express or implied discussions regarding potency future revenues from Diovan HCT and Exforge. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Diovan HCT and Exforge to be materially different from whatsoever future results, performance or achievements verbalized or implied by such statements. There can be no vouch that Diovan HCT and Exforge will achieve any particular levels of receipts in the future. In particular, management's expectations regarding Diovan HCT and Exforge could be affected by, among early things, the company's ability to obtain or keep patent or other proprietary intellectual property protection; contention in general; government, industry and general public pricing pressures; unexpected regulatory actions or delays or authorities regulation mostly; unexpected clinical trial results, including unexpected new clinical data and unexpected extra analysis of existing clinical data; and other risks and factors referred to in Novartis AG's electric current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions bear witness incorrect, factual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the selective information in this press release as of this date and does not contract any obligation to update any advanced statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis AG provides healthcare solutions that treat the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to charles Herbert Best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the merely company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies hire approximately 98,000 full-time associates and operate in over 140 countries around the world. For more than information, please visit http://www.novartis.com.
References
[1] JNC-VII, The Seventh Report on the Joint National 139% on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, JAMA 2003: 289(19):2560-72
[2] Dahl�f B, Poulter NR, Wedel H, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005;366:895-906
[3] Ofili EO. Dispelling the Myth of "Aggressive" Antihypertensive Therapy. J Clin Hypertens. 2006 Jan;8(1 Suppl 1):4-11
[4] World Health Organization. "Main causes of death and spherical burden of disease (DALYs), world, all ages, projections for 2005." Available at: http://www.who.int/whosis/highlight05.png (accessed 26 June 2008)
[5] Saleh SS, Szebenyi S, Carter JA, et al. Patterns and Associated Health Services Costs of Antihypertensive Drug Modifications. J Clin Hypertens. 2008 January; 10(1):43-50
[6] Weber MA, Ruilope L, Giles T, et al. First-Step Use of Fixed-Dose Combination Treatment in Stage 2 Hypertensive Patients: Has the Time Come? J Clin Hypertens. 2007 April;9(4):276-284
[7] Sica D. Fixed-Dose Combination Antihypertensive Drugs. Do They Have a Role in Rational Therapy? Drugs. 1994 Jul;48(1):16-24
[8] Chen K. Patient satisfaction with antihypertensive drug therapy. Journal of Human Hypertension (2005) 19, 793-799
[9] Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics - 2008 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008: 117:e25-e146
[10] Kearney PM, Whelton M, Reynolds K, et al.. Global burden of hypertension: analysis of cosmopolitan data. The Lancet; 365: 217-223
[11] Diovan HCT [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008
[12] Pool JL, Glazer R, Weinberger M, et al. Comparison of Valsartan/ Hydrochlorothiazide Combination Therapy at Doses Up to 320/25 mg Versus Monotherapy: A Double-Blind, Placebo-Controlled Study Followed by Long-Term Combination Therapy in Hypertensive Adults. Clinical Therapeutics 2007: 29 (1):61-73
[13] Exforge [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008
Novartis
http://www.novartis.com
View drug info on Diovan.
More info
Subscribe to:
Posts (Atom)